Funded Biotechnology Startups in Lyon
Lyon's biotechnology sector has generated 16 tracked financing rounds between December 2021 and August 2025, ranging from a $540K raise by CTIBiotech to Ma…
Lyon's biotechnology sector has generated 16 tracked financing rounds between December 2021 and August 2025, ranging from a $540K raise by CTIBiotech to MaaT Pharma's $44M round closed in July 2025. The two largest deals — MaaT Pharma ($44M) and Mablink Bioscience's $30M Series A in October 2022 — together dwarf most of the remaining rounds, which cluster between $3M and $10M. Six rounds have closed in 2025 alone, a pace that includes Osivax ($20M, August), ENYO Pharma's Series C ($7M, June), and a Series B for organ-on-chip instrumentation company NETRI ($5M, February).
The therapeutic mix skews toward drug development — vaccine platforms, microbiome therapeutics, metabolic disease, and antibody-drug conjugates each have representation — alongside enabling-technology companies and a nascent food biotech thread through Bon Vivant and Susu. Round-type disclosure is sparse; most deals carry a "Series Unknown" designation, a pattern consistent with French life-science financings that frequently combine private equity with public instruments such as EIC funding, making clean stage attribution difficult.
Most recent rounds
16 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Lyon biotech companies in this list?
MaaT Pharma leads with $44M raised in July 2025, followed by Mablink Bioscience's $30M Series A in October 2022 and Osivax's $20M in August 2025. Those three rounds account for the majority of disclosed capital across the 16 companies shown.
How active has Lyon biotech funding been in 2025 relative to earlier years?
Six of the 16 rounds closed in 2025 — Osivax, MaaT Pharma, ENYO Pharma, Allogenica, Adocia, and NETRI — spanning February through August, making it the most represented single calendar year in this dataset. By contrast, 2022 and 2023 each produced three rounds, and 2024 contributed three as well.
Which round stages are actually named in this dataset, and how common is the 'Series Unknown' label?
The majority of rounds carry no defined stage label and appear as Series Unknown, which is common in French biotech deals that often blend EIC grants, public instruments, and private equity. Named stages include a Seed (Ervaccine Technologies, $5M), Series A (Mablink Bioscience, $30M), Series B (NETRI, $5M), Series C (ENYO Pharma, $7M), and one Post-IPO Equity round (erytech, $8M). Bon Vivant's round amount is undisclosed entirely.
What therapeutic and application areas do these Lyon companies cover?
The set spans vaccine platforms (Osivax, Ervaccine Technologies), microbiome-based therapeutics (MaaT Pharma), metabolic and diabetes drug development (Adocia, Poxel), antibody-drug conjugates (Mablink Bioscience), 3D tissue modeling and cell therapy tools (CTIBiotech, NETRI), rare disease (Meletios Therapeutics, Lys Therapeutics), and food biotechnology (Bon Vivant, Susu).
Is there any post-IPO company among these funded Lyon biotech firms?
erytech completed a $8M Post-IPO Equity round in December 2021, the only post-IPO financing in this set. All other companies in the list are at private venture stages ranging from seed to late-stage rounds.
What is the smallest disclosed funding amount in this dataset?
CTIBiotech raised $540K in June 2024, the smallest disclosed figure among the 16 companies. Lys Therapeutics' $600K round from March 2023 is the next smallest, with both rounds sitting well below the dataset's median.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.